Advantice Connects On Second Swing To Support Nail Fungus Claims Challenged By Arcadia
Executive Summary
Without study it conducted after first review, Advantice wouldn’t have changed NAD’s conclusion on firm’s claim its product “starts improving nail appearance in just 2 days.” Without Arcadia’s premature publication of recommendation following NAD’s first review, Advantice wouldn’t have second chance.
You may also be interested in...
Arcadia Stubs Toe In Nail Fungus Ad Challenge, Giving Advantice Foot In Door On Appeal
Arcadia prohibited from arguing against Advantice’s appeal of National Advertising Division decision that Kerasal Fungal Nail Renewal ad claims weren’t supported. Arcadia violated confidentiality rule by publicizing NAD decision before the review was officially closed.
Athlete's Foot Firm Kicks Back On NAD Finding That Brand Is A Fungal Claim
Kramer Laboratories' claims for Fungi-Nail athlete's foot product referred to FDA and FTC after it refuses to comply with NAD's recommendation to modify the name. The firm, which agreed to modify packaging and commercial claims, was warned by FDA about the brand in 2005.
Ultrahuman Expands Wearable Medtech Production Into US After $35M Funding Round
Firm operating in London, India and United Arab Emirates says its “Ultra Factory” will open in Indiana within the next six months with end-to-end production based on its operational facility in India.